# ClinicalTrials.gov record NCT06967389

> PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06967389-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06967389-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06967389-semaglutide-v1.json
- Content SHA-256: `d38dd3813cef6bb31b8daa333a7436c21cd352d5e7874af0e783ec6a36279c76`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06967389 ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

## Sources

<a id="source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff"></a>
- **ClinicalTrials.gov record NCT06967389 · retained source version 2026-07-21:7b710d61cdff70f6fe52184fffd8cf70c77aaf39863edb86af41be375ef903f8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06967389) (`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06967389." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06967389-semaglutide-v1.json SHA-256: d38dd3813cef6bb31b8daa333a7436c21cd352d5e7874af0e783ec6a36279c76.